



# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

StockExchange-BSE letters/MM:676

August 11, 2017

BSE Ltd.  
Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai 400 001

**BSE Scrip Code : 506943**

**Stock Symbol: JBCHEPHARM**

Dear Sir,

**Sub : Press Release**

Enclosed is a press release we propose to issue on unaudited financial results for the quarter ended on June 30, 2017.

Kindly take the same on record.

Thanking you,

Yours faithfully,  
for J.B. Chemicals & Pharmaceuticals Limited

M. C. Mehta  
Company Secretary and Vice President - Compliance

Encl: As above



# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

## Press Release

BSE Scrip Code: 506943

NSE Symbol: JBCHEPHARM

Mumbai, August 11, 2017

### Unaudited Financial Results for Q 1- 2017-18

J.B. Chemicals & Pharmaceuticals Ltd. (JBCPL) today announced its standalone unaudited financial results for the quarter ended on June 30, 2017. The highlight of Y-o-Y results is as under:

| Particulars            | (Rs. in crores) |            |
|------------------------|-----------------|------------|
|                        | Q1-2017-18      | Q1-2016-17 |
| Sales                  | 277.68          | 305.85     |
| Other Operating income | 6.16            | 8.43       |
| Other Income           | 9.27            | 10.97      |
| Total Income           | 293.11          | 325.25     |
| EBITDA                 | 40.34           | 80.17      |
| Profit before tax      | 25.22           | 68.08      |
| Profit after tax       | 19.69           | 49.77      |
| EPS (Rs.) (FV 2)       | 2.32            | 5.88       |

Q1 witnessed lower sales both in domestic formulations as well as formulations exports.

The sales in the domestic market were impacted as stockists scaled down their purchases in anticipation of introduction of GST due to probable financial impact associated with the pre-GST inventory.

The domestic formulations sales at Rs. 122.76 crores were 8.27% lower YoY, while domestic market contrast media products sales at Rs. 10.06 crores were 7.29% lower YoY.

The overall formulations exports at Rs. 116.11 crores were 11.44% lower YoY. The exports of formulations in Global Business (other than Russia-CIS) at Rs. 85.47 crores were 11.14% lower YoY.

Sales in Global business were mainly impacted due to slow down in business caused by systemic issues in African market. During current quarter, the Company had successful launch of Glipizide Tablets in US market. We expect US sales to improve this year.

#### Registered Office:

Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

#### Corporate Office:

Chenergy IT Park  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380



# J. B. CHEMICALS & PHARMACEUTICALS LIMITED

However, exports for Russia-CIS market at Rs. 11.42 crores were 6.40% higher YoY. API sales at Rs. 30.54 crores were 17.18% higher YoY.

Due to the lower sales and nature of the cost which are mainly fixed, the Company saw de-growth in profits. Some of the other reasons were appreciation of Rupee against US \$ and higher manpower cost due to increase in domestic field force by over 600 people last quarter of the previous year. This investment in manpower is expected to bring additional sales going forward.

The performance of the Company has not been good for this quarter. However, development of strategy by trade on purchases and inventory holding consequent to introduction of GST will influence the Company's domestic sales going forward.

\*\*\*\*\*

## About JBCPL:

JBCPL, one of India's leading pharmaceutical companies, manufactures & markets a diverse range of pharmaceutical formulations, herbal remedies and APIs. JBCPL exports to many countries worldwide with presence in US, Europe, Australia, South Africa, other developing countries, Russia and CIS. The Company continues to invest in growing its share in the regulated markets in USA, Europe and Australia. JBCPL has a strong R & D and regulatory set-up for development of new drug delivery system and formulations, filing of ANDAs and DMFs. Its State-of-the-Art manufacturing facilities are approved by health authorities of important regulated markets.

For more information on JBCPL visit our website at [www.jbcpl.com](http://www.jbcpl.com). For more details, you may contact:

M.C. Mehta  
Company Secretary and Vice President- Compliance  
J. B. Chemicals & Pharmaceuticals Ltd.  
91 22 2439 5311

-- x --

## Forward Looking Statements:

*This Press Release may contain Forward Looking Statements regarding future events and future performance of J.B. Chemicals & Pharmaceuticals Ltd. that involve risks and uncertainties that could cause actual results to differ materially from those that may be indicated by such statements.*

### Registered Office:

Neelam Centre, B Wing, 4th Floor  
Hind Cycle Road, Worli  
Mumbai - 400 030

### Corporate Office:

Cnergy IT Park  
Unit A2, 3rd Floor, Unit A, 8th Floor  
Appa Saheb Marathe Marg, Prabhadevi  
Mumbai - 400 025

+91 22 2439 5200 / 2439 5500

+91 22 2431 5331 / 2431 5334

info@jbcpl.com

www.jbcpl.com

CIN: L24390MH1976PLC019380